RxDoctor Payments Data

Ricardo Gago Pinero, MD

Rheumatology · San Juan, PRNPI 1851555023

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by AbbVie at 57.0% of the total. Reporting peaked in 2024 at $2,597 and has fallen 60.2% since, to $1,033 in 2025.

$7,201in general payments, 2019–2025

Across 68 payments — averaging $105.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$977
  • GSK$516
  • Amgen$486
  • E.r. Squibb & Sons, L.L.C.$230
  • Sanofi$196
  • plus $694 from 8 others

What the payments were for

  • Consulting fees$3,75052%
  • Food & beverage$3,44748%
  • Education$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,201 in reported general payments places this provider in the 75th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,207
Medicare patients
84
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept73$542,773
Humira(Cf) PenAdalimumab76$525,221
Orencia ClickjectAbatacept56$335,819
ProliaDenosumab152$270,575
RinvoqUpadacitinib40$258,464
OrenciaAbatacept39$220,317
EnbrelEtanercept20$147,536
Humira(Cf)Adalimumab19$131,117
Xeljanz XrTofacitinib Citrate14$80,728
BenlystaBelimumab15$71,446
TymlosAbaloparatide17$45,382
MethotrexateMethotrexate Sodium766$10,886
Gabapentin1,097$7,538
Diclofenac Sodium351$7,171
Prednisone822$6,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Enbrel$486$418,111172 claims
AbbVieRinvoq, Humira(Cf)$4,102$389,58159 claims
E.r. Squibb & Sons, L.L.C.Orencia$230$220,31739 claims
GSKBenlysta$516$71,44615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →